Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to -$70.5 million.

  • Syndax Pharmaceuticals' Cash from Operations fell 1317.83% to -$70.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$310.9 million, marking a year-over-year decrease of 2009.39%. This contributed to the annual value of -$274.9 million for FY2024, which is 7117.14% down from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Cash from Operations stood at -$70.5 million for Q3 2025, which was down 1317.83% from -$87.8 million recorded in Q2 2025.
  • Syndax Pharmaceuticals' Cash from Operations' 5-year high stood at $100.7 million during Q4 2021, with a 5-year trough of -$95.2 million in Q1 2025.
  • Moreover, its 5-year median value for Cash from Operations was -$41.3 million (2023), whereas its average is -$41.8 million.
  • In the last 5 years, Syndax Pharmaceuticals' Cash from Operations soared by 74429.02% in 2021 and then tumbled by 12273.28% in 2022.
  • Over the past 5 years, Syndax Pharmaceuticals' Cash from Operations (Quarter) stood at $100.7 million in 2021, then tumbled by 122.73% to -$22.9 million in 2022, then plummeted by 80.61% to -$41.3 million in 2023, then tumbled by 38.79% to -$57.4 million in 2024, then fell by 22.91% to -$70.5 million in 2025.
  • Its last three reported values are -$70.5 million in Q3 2025, -$87.8 million for Q2 2025, and -$95.2 million during Q1 2025.